CD74 and neoplasm: One possible scenario involves a model where differential expression of CD74 and/or its various MIF co-receptors change as a result of tumor stage, immune effector cell infiltration, metabolic imbalance, and/or relative oxygenation; all of which would be expected to alter the relative phenotypic effects of soluble tumor-derived or immune effector cell-derived MIF in outside-in signaling.